Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 17/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 16/20 | 0.55 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14500390 | 0.90 | CDK9 (0.55) | CDK9CCNT1TBK1 | |
| SCHEMBL14500409 | 0.89 | APP (0.45) | CDK9CCNT1APP | |
| SCHEMBL14500414 | 0.89 | CDK9 (0.57) | CDK9CCNT1TBK1 | |
| SCHEMBL14500416 | 0.88 | CDK9 (0.54) | CDK9CCNT1TBK1 | |
| SCHEMBL5004934 | 0.87 | CDK9 (0.47) | CDK9CCNT1TBK1CNR1 | |
| SCHEMBL14500415 | 0.87 | CDK9 (0.57) | CDK9CCNT1TBK1 | |
| SCHEMBL5662093 | 0.87 | CDK9 (0.58) | CDK9CCNT1TBK1 | |
| SCHEMBL14500418 | 0.86 | CDK9 (0.60) | CDK9CCNT1TBK1 | |
| SCHEMBL14520938 | 0.85 | CDK9 (0.60) | CDK9CCNT1TBK1 | |
| SCHEMBL14520253 | 0.85 | CDK9 (0.57) | CDK9CCNT1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | BMX, ERBB2, FRK | CDK9 392/4885CCNT1 1682/4885TBK1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.